MRSA (methicillin-resistant staphylococcus aureus)

MRSA is presently a pathogen of global health concern. . They are S. aureus strains that are resistant to oxacillin, nafcillin and methicillin. They can also be resistant to all ß-lactam agents.  It can cause a variety of problems ranging from skin infections and sepsis to pneumonia and various types of bloodstream infections. The infections occur commonly among people in hospitals and healthcare facilities such as nursing homes, diagnostic centres and dialysis centres, who have less stable immune systems. The current arsenal of antibiotics available for the treatment of MRSA includes a topical agent, a limited number of oral agents.

 

  • Community-acquired MRSA (CA-MRSA)
  • Healthcare-associated MRSA (HA-MRSA)
  • Virulence Associated Factors of CA-MRSA
  • Antibiotic resistance
  • Recurrent MRSA Infections
  • Oral and intravenous agents
  • Topical agents
  • Vancomycin, Clindamycin and linezolid
  • Pneumonia (HAP/VAP)
  • Chronic osteomyelitis (COM)
  • Skin and soft tissue infections

Related Conference of MRSA (methicillin-resistant staphylococcus aureus)

January 21-22, 2021

7th Rare Diseases and Orphan Drugs

Vienna, Austria
February 15-16, 2021

8th International Congress on Infectious Diseases

London, UK
May 10-11, 2021

4th Global Experts Meeting on Infectious Diseases

Singapore City, Singapore
August 16-17, 2021

13th Global Infections Conference

Tokyo, Japan
September 06-07, 2021

11th World Congress on Rare Diseases and Orphan Drugs

Berlin, Germany

MRSA (methicillin-resistant staphylococcus aureus) Conference Speakers

Recommended Sessions

Related Journals

Are you interested in